(Q44502844)

3 December 2017

Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia (English)

1 reference

3 December 2017

0 references

Veena Kumari

4

0 references

author name string

Tonmoy Sharma

series ordinal

1

1 reference

PubMed ID

12845415

3 December 2017

Catherine Hughes

series ordinal

2

1 reference

PubMed ID

12845415

3 December 2017

William Soni

series ordinal

3

1 reference

3 December 2017

4 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

169

1 reference

3 December 2017

3-4

1 reference

3 December 2017

398-403

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-003-1506-y

3 December 2017

0 references

cites work

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

12 December 2020

A proposed pathological model in the hippocampus of subjects with schizophrenia

1 reference

12 December 2020

A review of longitudinal studies of cognitive functions in schizophrenia patients

1 reference

12 December 2020

Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia

1 reference

12 December 2020

Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects.

1 reference

12 December 2020

Effects of clozapine on cognitive function in schizophrenia

1 reference

12 December 2020

Tardive dyskinesia: prevalence, incidence, and risk factors

1 reference

12 December 2020

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

12 December 2020

Effects of clozapine on awareness of illness and cognition in schizophrenia

1 reference

12 December 2020

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Neurocognitive and social functioning in schizophrenia.

1 reference

12 December 2020

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Cognitive effects of conventional and atypical antipsychotics in schizophrenia

1 reference

12 December 2020

Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?

1 reference

12 December 2020

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

1 reference

12 December 2020

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

12 December 2020

Longitudinal study of symptoms and cognitive function in chronic schizophrenia.

1 reference

12 December 2020

Neuropsychological change in schizophrenia after 6 weeks of clozapine

1 reference

12 December 2020

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

12 December 2020

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

12 December 2020

Cognitive deficits and cognitive training in schizophrenic patients: a review

1 reference

12 December 2020

Cognitive and behavioral precursors of schizophrenia.

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

Neuropsychological functioning in first-episode psychosis--evidence of specific deficits.

1 reference

12 December 2020

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

12 December 2020

10.1007/S00213-003-1506-Y

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12845415